Giulio Superti-Furga
| Giulio Superti-Furga | |
|---|---|
 Giulio Superti-Furga, Ph.D. in 2011 | |
| Born |
17 May 1962 Milan, Italy |
| Nationality | Italian |
| Fields | Molecular and Systems Biology |
| Institutions | CeMM |
Giulio Superti-Furga (born 17 May 1962 in Milan) is an Italian molecular and systems biologist based in Vienna, Austria. He is the Scientific Director of CeMM; the Research Center for Molecular Medicine of the Austrian Academy of Sciences.
Amongst his most significant scientific achievements to date are the elucidation of basic regulatory mechanisms of tyrosine kinases in human cancers and the discovery of fundamental organization principles of the proteome of higher organisms, which is one of the most highly cited papers in the field. His work has directly contributed to a systems-level understanding of pathogen infections in host cells and of the mechanism of action of specific drugs. He is an advocate for the adoption of systems biology approaches for medicine and in particular for drug discovery and aims to bridge basic research and the clinical world.
Giulio Superti-Furga has published some 150 manuscripts listed in Pubmed[1] and some 240 publications in ISI Web of Science[2] that have been collectively cited over 17,000 times. His current work focuses on protein complexes, molecular networks and drugs relevant for leukemia and host immune defense mechanisms against pathogens.
CV
Giulio Superti-Furga was educated at the German School of Milan (DSM) in Milan, Italy. He performed his undergraduate and graduate studies in Molecular Biology at the University of Zurich, at Genentech Inc. in San Francisco and at the Research Institute of Molecular Pathology (IMP) in Vienna. Giulio Superti-Furga was a post-doctoral fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg and became Team Leader in 1995. From 1997 to 2000 he served as Guest Professor of Molecular Biology at the University of Bologna, Italy. In 2000, he co-founded the biotech company Cellzome Inc. and served as Scientific Director.[3] Since 2005 he has been Scientific Director of CeMM; the Research Center for Molecular Medicine of the Austrian Academy of Sciences. Giulio Superti-Furga is a Visiting Professor of Molecular Pharmacology at the Medical University of Vienna and is on the Scientific Advisory Board of several institutions. Giulio Superti-Furga chairs the board of the EMBL Alumni Association,[4] which has ~2,000 members. In 2009, he was awarded the Knight Officer Order of Merit of the Republic of Italy for his contributions to science. In 2010 he co-founded the biotechnology company Haplogen GmbH in Vienna, a CeMM spin-off focused on haploid genetics.[5] In February 2013 the eight nominees of the Board of the University of Vienna elected Giulio Superti-Furga as ninth member to serve for a five-year term.[6] He is married and has two children.
Honors
- 2004-2009: Faculty of 1000 Biology, Member, Genomics Section
- 2005: European Molecular Biology Organization (EMBO), Member
- 2007: Austrian Academy of Sciences, Corresponding Member
- 2008: German Academy of Sciences Leopoldina, Member[7]
- 2009: Order of Merit of the Republic of Italy, Knight Officer
- 2009: Austrian Society of Allergology and Immunology, Karl Landsteiner Prize[8]
- 2009: European Research Council, Advanced Investigator Grant
- 2010: European Academy of Cancer Sciences, Fellow
- 2010: Austrian Academy of Sciences, Full Member[9]
- 2011: Austrian Scientist of the Year[10]
- 2011: Prize of the City of Vienna for Natural Sciences[11]
- 2013-2018: Board of the University of Vienna, elected member
- 2014: Academia Europaea, Member[12]
Bibliography
(selected)
- Gavin, A.C. et al.: Functional organization of the yeast proteome by systematic analysis of protein complexes. 'Nature. 2002; 415:141–147, doi:10.1038/415141a..
- Pluk, H. et al.: Autoinhibition of c-Abl. Cell. 2002; 108:247–259, doi:10.1016/S0092-8674(02)00623-2.
- Hantschel, O. et al.: A Myristoyl / Phosphotyrosine Switch Regulates c-Abl. Cell. 2003; 112:845–857, doi:10.1016/S0092-8674(03)00191-0.
- Brown, D. and Superti-Furga, G.: Rediscovering the sweet spot in drug discovery. Drug Discovery Today. 2003; 8:1067–1077, ISSN 1359-6446.
- Bouwmeester, T. et al.: A physical and functional map of the human TNF-/NF-B signal transduction pathway. Nature Cell Biology. 2004; 6:97–105, doi:10.1038/ncb1086.
- Gavin, A.C. et al.: Proteome survey reveals modularity of the yeast cell machinery. Nature. 2006; 440(7084):631-6, doi:10.1038/nature04532.
- Burckstummer, T. et al.: An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat. Methods. 2006; 3(12):1013-9, doi:10.1038/nmeth968.
- Rix, U. et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood. 2007; 110(12):4055-63, doi:10.1182/blood-2007-07-102061.
- Henney, A. and Superti-Furga, G.: A network solution. Nature. 2008; 455(7214):730-1, doi:10.1038/455730a.
- Bürckstümmer, T. et al.: An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol. 2009; 10(3):266-72, doi:10.1038/ni.1702.
- Brehme, M., Hantschel, O. et al.: Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A. 2009; 106(18):7414–9, doi:10.1073/pnas.0900653106.
- Dixit, E. et al.: Peroxisomes are signaling platforms for antiviral innate immunity. Cell. 2010; 141(4):668-81, doi: 10.1016/j.cell.2010.04.018.
- Rix, U. et al.: A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia. 2010, 24: 44–50, doi:10.1038/leu.2009.228.
- Baumann, C. et al.: CD14 is a co-receptor of Toll-like receptors 7 and 9. J Exp Med. 2010, 207(12): 2689-701, doi: 10.1084/jem.20101111.
- Pichlmair, A. et al.: IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol. 2011, 12(7):624-30, doi: 10.1038/ni.2048.
- Grebien, F. et al.: Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell. 2011, 147(2):306-19, doi: 10.1016/j.cell.2011.08.046.
- Winter, G.E. et al.: Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol. 2012; 8(1):905-12, doi: 10.1038/nchembio.1085.
- Varjosalo, M. et al.: Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat. Methods. 2013; 10(4): 307-14, doi: 10.1038/nmeth.2400.
- Huber, K.V. et al.: Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy. Nature. 2014; 508(7495):222-7, doi: 10.1038/nature13194.
References
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/
- ↑ http://thomsonreuters.com/thomson-reuters-web-of-science/
- ↑ http://www.nature.com/naturejobs/science/articles/10.1038/nj7078-888a
- ↑ http://www.embl-hamburg.de/aboutus/alumni/aboutus/board/profiles/
- ↑ http://www.haplogen.com
- ↑ http://www.ots.at/presseaussendung/OTS_20130227_OTS0155/eva-nowotny-uebernimmt-universitaetsratsvorsitz-von-max-kothbauer
- ↑ http://www.oeaw.ac.at/deutsch/aktuell/presse/detail/archive/2008/may/-/giulio-superti-furga-zum-mitglied-der-leopoldina-gewaehlt-595.html
- ↑ offizielle homepage der ÖGAI
- ↑ http://www.oeaw.ac.at/deutsch/about/personen/mitarbeiterinnen/personendetails.html?user_oeawperssuche_pi1[id]=12800
- ↑ de:Österreicher des Jahres#2011
- ↑ Artikel zur Ehrung durch die Stadt Wien
- ↑ http://www.ae-info.org/ae/User/Superti-Furga_Giulio